Aspirin triggers antiinflammatory 15-epi-lipoxin A 4 and inhibits thromboxane in a randomized human trial
Open Access
- 7 October 2004
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 101 (42), 15178-15183
- https://doi.org/10.1073/pnas.0405445101
Abstract
There is increasing evidence that aspirin initiates biosynthesis of novel antiinflammatory mediators by means of interactions between endothelial cells and leukocytes. These mediators are classified as aspirin-triggered 15-epi-lipoxins. Such compounds may account at least in part for aspirin's clinical benefits, which are distinct from the well appreciated action of aspirin as a platelet inhibitor. Here, we addressed whether aspirin-triggered 15-epilipoxinA4 (ATL) formation is aspirin-dependent in humans and its relationship to aspirin's antiplatelet activity. We conducted a randomized clinical trial among 128 healthy subjects allocated to placebo or to 81-, 325-, or 650-mg daily doses of aspirin for 8 weeks. Plasma thromboxane (TX)B2, an indicator of platelet reactivity, and ATL were assessed from blood collected at baseline and at 8 weeks. Plasma ATL levels significantly increased in the 81-mg aspirin group (0.25 ± 0.63 ng/ml, P = 0.04), with borderline increases in the 325-mg group (0.16 ± 0.71 ng/ml) and no apparent significant changes in the 650-mg group (0.01 ± 0.75 ng/ml, P = 0.96). When ATL and TXB2 were compared, levels changed in a statistically significant and opposite direction (P < 0.01) for all three aspirin doses. These results demonstrated that low-dose aspirin (81 mg daily) initiates production of antiinflammatory ATL opposite to the inhibition of TX. Monitoring ATL may represent a simple clinical parameter to verify an individual's vascular leukocyte antiinflammatory response with low-dose aspirin treatment. These results also emphasize the importance of cell-cell interactions in the modulation of hemostatic, thrombotic, and inflammatory processes.This publication has 32 references indexed in Scilit:
- What are all the things that aspirin does?BMJ, 2003
- Relative contribution of acetylated cyclooxygenase (COX)‐2 and 5‐lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirinThe FASEB Journal, 2003
- Aspirin and the Prevention of Colorectal CancerThe New England Journal of Medicine, 2003
- Inflammation in atherosclerosisNature, 2002
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsThe New England Journal of Medicine, 2002
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2Science, 2002
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenThe New England Journal of Medicine, 1997
- Targets for Antiinflammatory DrugsAnnual Review of Pharmacology and Toxicology, 1995
- The Genesis of OresScientific American, 1991
- AspirinScientific American, 1991